Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cannabinoids, Neural Synchrony, and Information Processing

NCT00708994
Conditions
Cannabis, Psychotic Disorders
Interventions
THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition

NCT02404688
Conditions
Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
Interventions
Active delta-9-THC, Placebo, Active Ethanol
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Delta-9-THC and Iomazenil in Healthy Humans

NCT00982982
Conditions
Schizophrenia, Mental Disorders, Psychotic Disorders
Interventions
THC and Iomazenil, Placebo (control)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Multiple Myeloma
Interventions
Allogeneic HSCT, Fludarabine, Melphalan, Bortezomib, Ixazomib, Placebo
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Tampa, Florida + 11 more
Conditions
Chronic Hepatitis B Virus, Pediatric
Interventions
Entecavir, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
15
States / cities
San Francisco, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more
Conditions
Major Depression Disorder, Depression
Interventions
DMT-Medium Dose, DMT-Low Dose, THC-Medium Dose, THC-Low Dose
Drug
Lead sponsor
Deepak C. D'Souza
Other
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cannabinoids and Cerebellar-Motor Functioning

NCT01853020
Conditions
Cannabis, Psychotic Disorders
Interventions
THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 35 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

NCT01775358
Conditions
Growth Hormone Deficiency
Interventions
ALRN-5281 0.015 mg/kg, ALRN-5281 0.05 mg/kg, ALRN-5281 0.15 mg/kg, Placebo 0.015 mg/kg, Placebo 0.05mg/kg, Placebo 0.15mg/kg
Drug
Lead sponsor
Aileron Therapeutics, Inc.
Industry
Eligibility
20 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
43
States / cities
Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more
Conditions
Cannabis, Ketamine
Interventions
Active Delta-9-THC, Placebo Delta-9-THC, Active Ketamine, Placebo Ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
West Haven, Connecticut